S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
Log in

NASDAQ:VRNA - VERONA PHARMA P/S Stock Price, Forecast & News

$3.99
+0.04 (+1.01 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$3.92
Now: $3.99
$4.10
50-Day Range
$3.70
MA: $4.24
$4.85
52-Week Range
$3.65
Now: $3.99
$10.69
Volume17,835 shs
Average Volume23,976 shs
Market Capitalization$52.55 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.98
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRNA
CUSIPN/A
Phone44-20-3283-4200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.40 per share

Profitability

Net Income$-26,560,000.00

Miscellaneous

Employees22
Market Cap$52.55 million
Next Earnings Date2/25/2020 (Estimated)
OptionableNot Optionable

Receive VRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.


VERONA PHARMA P/S (NASDAQ:VRNA) Frequently Asked Questions

What is VERONA PHARMA P/S's stock symbol?

VERONA PHARMA P/S trades on the NASDAQ under the ticker symbol "VRNA."

How were VERONA PHARMA P/S's earnings last quarter?

VERONA PHARMA P/S (NASDAQ:VRNA) released its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by $0.06. View VERONA PHARMA P/S's Earnings History.

When is VERONA PHARMA P/S's next earnings date?

VERONA PHARMA P/S is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for VERONA PHARMA P/S.

What price target have analysts set for VRNA?

2 equities research analysts have issued 12 month target prices for VERONA PHARMA P/S's stock. Their forecasts range from $17.00 to $58.00. On average, they anticipate VERONA PHARMA P/S's stock price to reach $37.50 in the next twelve months. This suggests a possible upside of 839.8% from the stock's current price. View Analyst Price Targets for VERONA PHARMA P/S.

What is the consensus analysts' recommendation for VERONA PHARMA P/S?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VERONA PHARMA P/S in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VERONA PHARMA P/S.

Has VERONA PHARMA P/S been receiving favorable news coverage?

Media stories about VRNA stock have been trending somewhat positive on Friday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. VERONA PHARMA P/S earned a daily sentiment score of 1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for VERONA PHARMA P/S.

Are investors shorting VERONA PHARMA P/S?

VERONA PHARMA P/S saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 600 shares, an increase of 500.0% from the October 31st total of 100 shares. Based on an average trading volume of 4,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.0% of the company's stock are sold short. View VERONA PHARMA P/S's Current Options Chain.

Who are some of VERONA PHARMA P/S's key competitors?

What other stocks do shareholders of VERONA PHARMA P/S own?

Who are VERONA PHARMA P/S's key executives?

VERONA PHARMA P/S's management team includes the folowing people:
  • Dr. Jan-Anders Karlsson, CEO & Exec. Director (Age 64)
  • Mr. Piers John Morgan, Chief Financial Officer (Age 53)
  • Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 52)
  • Ms. Victoria Stewart, Director of Communications
  • Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 57)

When did VERONA PHARMA P/S IPO?

(VRNA) raised $61 million in an initial public offering (IPO) on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

Who are VERONA PHARMA P/S's major shareholders?

VERONA PHARMA P/S's stock is owned by many different of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.23%) and IHT Wealth Management LLC (0.16%).

Which major investors are buying VERONA PHARMA P/S stock?

VRNA stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc. and IHT Wealth Management LLC.

How do I buy shares of VERONA PHARMA P/S?

Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is VERONA PHARMA P/S's stock price today?

One share of VRNA stock can currently be purchased for approximately $3.99.

How big of a company is VERONA PHARMA P/S?

VERONA PHARMA P/S has a market capitalization of $52.55 million. The company earns $-26,560,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. VERONA PHARMA P/S employs 22 workers across the globe.View Additional Information About VERONA PHARMA P/S.

What is VERONA PHARMA P/S's official website?

The official website for VERONA PHARMA P/S is http://www.veronapharma.com/.

How can I contact VERONA PHARMA P/S?

VERONA PHARMA P/S's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]


MarketBeat Community Rating for VERONA PHARMA P/S (NASDAQ VRNA)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  216 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  323
MarketBeat's community ratings are surveys of what our community members think about VERONA PHARMA P/S and other stocks. Vote "Outperform" if you believe VRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel